Olipass Corp
244460
Company Profile
Business description
Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.
Contact
16-4, 16 Beon-gil, Dongbaek Jungang-ro
Ace Dongbaek Tower 20th Floor
Giheung-gu
Yongin17015
KORT: +82 3180608200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
39
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,015.40 | 48.70 | 0.54% |
CAC 40 | 7,861.96 | 4.60 | 0.06% |
DAX 40 | 24,262.22 | 44.85 | 0.19% |
Dow JONES (US) | 44,343.88 | 289.11 | -0.65% |
FTSE 100 | 9,136.94 | 0.62 | 0.01% |
HKSE | 25,176.93 | 347.52 | -1.36% |
NASDAQ | 21,071.64 | 26.65 | -0.13% |
Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
S&P 500 | 6,348.12 | 22.74 | -0.36% |
S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
SSE Composite Index | 3,615.72 | 6.01 | 0.17% |